Robert A. Shalwitz
Fondateur chez Invirsa, Inc.
Profil
Robert A.
Shalwitz is the founder of Akebia Therapeutics, Inc. (founded in 2007), Aerpio Therapeutics, Inc. (founded in 2011), and Invirsa, Inc. (founded in 2014).
At Aerpio Therapeutics, he held the title of Chief Marketing Officer from 2011 to 2014.
At Invirsa, Inc., he is currently the President, Chief Executive Officer & Director.
Dr. Shalwitz's former jobs include Medical Director at Abbott Laboratories, Vice President-Clinical Development at Reliant Pharmaceuticals LLC, and Chief Operating Officer at Heart Metabolics Ltd.
Dr. Shalwitz holds a doctorate degree from the State University of New York at Buffalo and an undergraduate degree from the University of Michigan.
Postes actifs de Robert A. Shalwitz
| Sociétés | Poste | Début |
|---|---|---|
Invirsa, Inc.
 Invirsa, Inc. Medical/Nursing ServicesHealth Services Invirsa, Inc. provides medical services. The company was founded by Robert Shalwitz on November 24, 2014 and is headquartered in Bexley, OH. | Fondateur | 24/11/2014 |
Anciens postes connus de Robert A. Shalwitz
| Sociétés | Poste | Fin |
|---|---|---|
| AKEBIA THERAPEUTICS, INC. | Fondateur | 31/12/2014 |
Heart Metabolics Ltd.
 Heart Metabolics Ltd. BiotechnologyHealth Technology Heart Metabolics Ltd. operates as a biopharmaceutical company that engages in developing new treatments for orphan disease including cardio-metabolic diseases. The firm provides drugs to treat heart failure for hypertrophic cardiomyopathy patients. The company was founded by Michael Paul Frenneaux and Houshman Ashrafian in 2004 and is headquartered in Dublin, Ireland. | Directeur des opérations | - |
Aerpio Therapeutics, Inc.
 Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Fondateur | - |
| ABBOTT LABORATORIES | Directeur Technique/Scientifique/R&D | - |
Reliant Pharmaceuticals LLC
 Reliant Pharmaceuticals LLC Miscellaneous Commercial ServicesCommercial Services Reliant Pharmaceuticals, Inc. sells, markets and develops cardiovascular pharmaceutical products. The company focuses on marketing promotionally sensitive pharmaceutical products to the primary care, cardiovascular and specialist physician markets in the United States. The company is headquartered in Liberty Corner, NJ | Directeur Technique/Scientifique/R&D | - |
Formation de Robert A. Shalwitz
| University of Michigan | Undergraduate Degree |
| State University of New York at Buffalo | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| AKEBIA THERAPEUTICS, INC. | Health Technology |
| ABBOTT LABORATORIES | Health Technology |
| Entreprise privées | 4 |
|---|---|
Reliant Pharmaceuticals LLC
Reliant Pharmaceuticals LLC Miscellaneous Commercial ServicesCommercial Services Reliant Pharmaceuticals, Inc. sells, markets and develops cardiovascular pharmaceutical products. The company focuses on marketing promotionally sensitive pharmaceutical products to the primary care, cardiovascular and specialist physician markets in the United States. The company is headquartered in Liberty Corner, NJ | Commercial Services |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Health Technology |
Heart Metabolics Ltd.
Heart Metabolics Ltd. BiotechnologyHealth Technology Heart Metabolics Ltd. operates as a biopharmaceutical company that engages in developing new treatments for orphan disease including cardio-metabolic diseases. The firm provides drugs to treat heart failure for hypertrophic cardiomyopathy patients. The company was founded by Michael Paul Frenneaux and Houshman Ashrafian in 2004 and is headquartered in Dublin, Ireland. | Health Technology |
Invirsa, Inc.
Invirsa, Inc. Medical/Nursing ServicesHealth Services Invirsa, Inc. provides medical services. The company was founded by Robert Shalwitz on November 24, 2014 and is headquartered in Bexley, OH. | Health Services |
